Pacific Biosciences Of California (PACB) Long-Term Debt Issuances (2013 - 2021)
Pacific Biosciences Of California (PACB) recorded quarterly Long-Term Debt Issuances of -$88000.0 in Q2 2021, down 100.01% quarter-over-quarter from $895.6 million in Q1 2021.
Pacific Biosciences Of California (PACB) Long-Term Debt Issuances (2013 - 2021) Analysis & Trends
Pacific Biosciences Of California's Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at -$88000.0 for Q2 2021.
- In Q2 2021, Long-Term Debt Issuances changed N/A year-over-year to -$88000.0; the TTM figure through Dec 2021 stood at $895.5 million (changed N/A YoY), while the FY2021 annual figure was $895.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances was -$88000.0 for Q2 2021 at Pacific Biosciences Of California, down from $895.6 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $895.6 million in Q1 2021 to a low of -$88000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 19.86 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | - |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 1.15 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 11.71 Mn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | - |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Pacific Biosciences Of California | 402.15 Mn | 126.19 Mn | 12.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -88,000.00 |
| Jun 30, 2021 | -88,000.00 |
| Mar 31, 2021 | 895.62 Mn |
| Mar 31, 2021 | 895.62 Mn |
| Mar 31, 2013 | 19.77 Mn |
| Mar 31, 2013 | 19.77 Mn |